Introduction: Expectant management reduces overtreatment in low risk but not intermediate risk localized prostate cancer. We assessed the use and predictors of expectant management to understand its uptake in practice in the United States.
Methods: Using the SEER (Surveillance, Epidemiology and End Results)-Medicare database, we conducted a retrospective cohort study of men 66 years or older diagnosed with low (25,506 patients) or intermediate risk (25, 597) localized prostate cancer between 2004 and 2011 and followed through December 31, 2012. We defined expectant management as 1) no definitive therapy and at least 1 prostate specific antigen test or repeat biopsy 4 to 12 months after diagnosis or 2) receiving definitive therapy after prostate specific antigen testing or repeat biopsy 7 to 12 months after diagnosis. We performed separate analyses for low and intermediate risk groups using multiple logistic regressions.
Results: For men diagnosed with prostate cancer in 2004 to 2011 expectant management increased from 22% to 43% in the low risk group and from 15% to 18% in the intermediate risk group. In the low risk group expectant management increased with age (adjusted OR 1.26 for age 71 to 75 years, 2.21 for 76 to 80 years, 6 .33 for greater than 80 years; all p <0.0001 compared to age 66 to 70 years). Expectant management uptake was higher among men with comorbidities (OR 1.29) and those residing in the Pacific region (adjusted OR 0.56 compared to East Coast).
Conclusions:
In United States practice utilization of expectant management has steadily increased in low risk prostate cancer and remained low in intermediate risk prostate cancer through time.
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Study received institutional review board exemption. We also investigated patient and physician characteristics associated with EM to inform the most recent data on the patterns and predictors of EM in U.S. oncology practice.
Materials and Methods

Data Source
We used the linked SEER-Medicare database for this analysis. Details about the SEER-Medicare database have been described elsewhere. 20 Briefly the SEER program is a population based tumor registry that records all incidences of cancer in 18 selected geographic areas, covering approximately 26% of the U.S. population. SEER collects patient demographics, tumor histology and pathology, first course of treatment and survival (through linkage with state death certificates). The Medicare program covers hospital, physician and outpatient services for the U.S. population 65 years old or older. This study was declared exempt from institutional review board approval.
Study Subjects
We included all males 66 years or older who were newly diagnosed with low or intermediate risk localized PCa from January 1, 2004 through December 31, 2011 and followed through December 31, 2012. We restricted the study sample to men 66 years or older to ensure we had at least 1 year of patient comorbidity history from the Medicare program (eligibility at 65 years). Low and intermediate risks of recurrence were based on definitions from the AUA, using PSA value at diagnosis (less than 10 ng/dl vs 10 to 20 ng/ dl), Gleason score (less than 7 vs 7) and clinical T-stage (T2a or less vs T2b). 21 We excluded men who 1) were missing information for 2 or 3 criteria, 2) were not enrolled in Medicare part A plus B or health maintenance organization care (due to lack of complete medical visit data), 3) died within a year after the PCa diagnosis (due to inadequate followup to classify initial treatment choice as EM or DT) or 4) received DT alone within 12 months after diagnosis. Additionally we considered repeat biopsy or PSA test within 3 months after diagnosis as being for confirmatory instead of monitoring purposes. Men who only had PSA or repeat biopsy performed within 3 months after diagnosis and no further records were excluded due to lack of followup data. A flowchart for generating the final patient population is presented in figure 1 .
Definitions of Expectant Management and Definitive Therapy
Study subjects were classified as undergoing EM or DT based on the use of curative intent treatment and monitoring procedures 12 months after diagnosis. The EM group included men who 1) did not undergo prostatectomy or radiation in the first year but had at least 1 PSA or biopsy performed during months 4 to 12 and 2) had PSA test or repeat biopsy completed during months 7 to 12 and before radiation or prostatectomy in the first year. We defined DT using records on the first course of treatment after diagnosis from the SEER database and claims from Medicare data. The DT group included men who 1) underwent prostatectomy or radiation during the first 6 months after diagnosis and 2) underwent prostatectomy or radiation during months 7 to 12 before the followup PSA test or repeat biopsy, if any, during months 7 to 12. HCPCS (Healthcare Common Procedure Coding System) codes for capturing the use and timing of relevant procedures are summarized in supplementary Appendix 1 (http://jurology.com/).
Covariates
We used SEER records to obtain age and year of diagnosis, race or ethnicity, registry region, marital status, tumor grade, Gleason score, clinical T-stage and PSA level at diagnosis. Using inpatient, outpatient and provider data from Medicare claims, we obtained comorbidities, including myocardial infarction, diabetes, fracture and stroke. We calculated the Charlson comorbidity index as a proxy of overall health. The presence of comorbidities was determined by either 1 inpatient primary diagnosis, 2 outpatient records at least 30 days apart, or 1 inpatient record and 1 outpatient record. We also ascertained where urologists were trained and years of practice at PCa diagnosis from the AMA Physician Masterfile.
Statistical Analysis
We first described population characteristics among the total population, the low risk group and the intermediate risk group. We then performed chi-square tests to compare sociodemographics and clinical characteristics between patients undergoing EM and DT. To identify predictors associated with EM use, we performed multiple logistic regression analyses with all covariates as independent factors. Results are expressed as adjusted ORs with 95% Wald CIs. Using multiple logistic regression, we also calculated adjusted probability of EM use to reveal absolute differences in EM use. 22 Tests were 2-sided. All data management and statistical analyses were performed using SASÒ, version 9.3.
Handling of Missing Data
We performed 2 multiple imputations using covariates available in the data set to estimate missing data in our final cohort. We first imputed PSA, Gleason score and T-stage data for men missing only 1 of these variables required to define PCa patient risk group ( fig. 2) . We then performed second imputations to obtain estimates for all other covariates with missing information. We conducted the main analyses in men with imputed data to avoid potential bias due to missing data and conducted sensitivity analyses among men with complete information.
Results
Study Population
We identified 25,506 low risk and 25,597 intermediate risk men who were diagnosed with localized PCa between 2004 and 2011 and followed through December 31, 2012. Median age at diagnosis was similar between groups (72 years in low risk and 73 years in intermediate risk group). In both groups the majority of patients were white, were married, resided in a metropolitan or urban area at diagnosis, had no major comorbidities and had PCa as the first cancer (table 1) . The majority of health care providers (87%) received medical training in the United States. Of the patients 36% received care from providers who had more than 30 years of practice since medical school graduation.
Patterns of Treatment in Low Risk Group
Approximately 30% of men were classified as undergoing EM during the first year after diagnosis (table 2) . Median patient age was 74 years for those undergoing EM and 71 years for those undergoing DT. Of patients who underwent EM 99% had at least 1 PSA test (median time after diagnosis 160 days) and 9% underwent repeat biopsy (206 days).
Of the DT group 92% underwent radiation and 8% underwent radical prostatectomy (median 78 and 79 days after diagnosis, respectively).
In unadjusted bivariate analyses of the low risk group EM recipients tended to be diagnosed in recent years, be older and unmarried, have more comorbidities and be from the Pacific region, compared to those undergoing DT. We found similar physician characteristics in both patient groups (table 2) .
Time Trends and Predictors Associated with EM
In the low risk group we noted an increasing trend in favor of EM vs DT use during 2004 to 2011 (adjusted probability increased from 22% to 43%, adjusted OR 2.83 for EM use in 2011 vs 2004, table 3). Additionally EM uptake increased substantially with increasing patient age (65% vs 22%, adjusted OR 6.33, 95% CI 5.66e7.08 for men older than 80 vs 66 to 69 years).
In the adjusted analyses of the low risk group we identified other predictors of EM use, including white race and history of cancer. Additionally EM use varied considerably by geographic region, with the Eastern region having a lower uptake of EM compared to the Pacific region (adjusted OR 0.56, 95% CI 0.52, 0.60). EM uptake was higher in men with more comorbidities (OR 1.30, 95% CI 1.17, 1.45).
We found determinants of EM use to be similar between the low risk and intermediate risk groups, except that EM use remained stable through time in the intermediate risk group (fig. 2 ). In our sensitivity analyses using men who had complete information for risk grouping we obtained the same predictors of EM with similar estimates (supplementary Appendixes 2 and 3, http://jurology.com/). 
Discussion
In this large population based study we observed that EM uptake for low risk localized PCa in U.S. urological practice has greatly increased, from 22% in 2004 to 43% in 2011. We noted that only 9% of these patients followed AS with a repeat biopsy during the first year after diagnosis. The findings alert us to possible barriers for care providers and patients in choosing EM and adhering to an AS protocol.
We also found a much lower percentage of EM use in the intermediate risk group and a lack of increase in recent years, consistent with evidence-based clinical management guidelines that recommend DT for this group. Nevertheless, it is noteworthy that 18% of these patients underwent EM and did not receive timely DT within the first year after diagnosis. We found EM use in U.S. urological practice to be greatest in 2011, at 43% (which was lower than expected), suggesting barriers to EM adoption outside clinical trial settings. According to the National Institutes of Health consensus development conference in 2011, an estimated 50% of men with low risk localized PCa should be recommended for AS. 23 The observed low use of EM may be due to uncertainty regarding the appropriateness, timing and patient selection of EM in practice. Specifically variation in EM research protocols or patient care pathways has led to conflicting findings regarding the comparative benefit to DT, which may reduce the enthusiasm for EM by some urologists. In the absence of randomized controlled trials validating treatment choices for localized prostate cancer, practitioners may have recommended DT until longer term evidence for EM emerged after 2010. Additionally during the study period there was inadequate guidance for providers regarding criteria for starting and stopping AS primarily due to uncertainty regarding the validity of varying eligibility criteria and even greater variability in triggers for shifting from EM to DT. Along with the absence of consensus guidelines from major urology professional organizations on the use of EM, such uncertainty may also have made providers hesitant to use EM. It is unclear how best to select patients for EM. Recent studies have suggested that magnetic resonance imaging and serum and tumor based markers, such as PSA isoforms, may improve patient selection for EM. 24 Additionally several genomic testing tools are commercially available to urologists for identifying low risk localized PCa for AS. 25 Although the clinical usefulness of these selection tools is still under research, development and integration of these tools for individualized AS protocols should increase AS use in the near future.
Higher uptake of EM in men of advanced age and with more comorbidity may reflect patient and physician preference for a conservative intervention policy among patients for whom the competing risk of death is greater due to shorter life expectancy. Increased EM use in unmarried men is consistent with the literature that married men are usually treated more aggressively than unmarried men. 26, 27 Our finding of higher use of EM among white vs black patients needs further investigation. Regional variation in medical practice has been reported, and reasons behind this phenomenon may include variations in regional practice styles, reimbursement policies of local institutions and level of patient/physician shared decision making. 28 Although provider preference has been recognized to have an important role in the management of low risk prostate cancer, 29 our data did not show EM adoption to be affected by provider medical school training or years of practice. This finding may be due to the requirements for U.S. medical licensure, including residency training at U.S. institutions for most foreign physicians and continued medical education during practice. Additionally medical school training and years of practice are not likely to accurately reflect provider knowledge or perceptions of EM, or the extent to which providers discuss the risks and benefits of EM vs conventional DT with patients.
A major strength of this study is the large population, which reflects urological practice in nonclinical trial settings in the United States. Moreover, detailed ascertainment of cancer related treatment from registry data and claims data allowed us to correctly identify patients with or without DT after PCa diagnosis. This study is limited in the lack of some important factors for treatment choices, including Epstein criteria for high volume Gleason score, receipt of a confirmatory biopsy, patient and physician preference, and patient accessibility to medical care, although we evaluated patient residency in urban or rural area as a proxy for access to care and found no difference in EM use. The study findings may not be generalizable to patients without continuous enrollment in Medicare and not covered by a health maintenance organization. Finally, there has been a warning regarding PSA value errors in the SEER-Medicare data, 30 which affected approximately 5% of risk groups.
Conclusions
This large population based study demonstrated steadily increasing adoption of EM in men with low risk PCa but not in men with intermediate risk cancer, whose receipt of EM remained stable through 2012. The substantial variation of EM use by region suggests a need for more evidence to develop clinical consensus about selecting optimal patient populations for EM, especially regarding men with intermediate risk disease, younger men and men without comorbidities. This information will be important as the field moves toward using personalized risk categorization for optimal treatment.
